Cargando…
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
In the combined use of bronchodilators of different classes, ie, long-acting β(2)-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), bronchodilation is obtained both directly, through LABA-mediated stimulation of β(2)-adrenergic receptors, and indirectly, through LAMA-mediated inhibiti...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468951/ https://www.ncbi.nlm.nih.gov/pubmed/26089659 http://dx.doi.org/10.2147/COPD.S72858 |